(Q36610996)

15 August 2017

1 reference

title

Novel pharmacological targets for the treatment of Parkinson's disease (English)

1 reference

15 August 2017

1 reference

10

1 reference

15 August 2017

Jonathan Brotchie

3

0 references

Erwan Bezard

Erwan Bezard

2

0 references

Frédéric Calon

Frédéric Calon

4

0 references

Anthony H V Schapira

1

Anthony H V Schapira

1 reference

15 August 2017

Michael A Schwarzschild

12

Michael A Schwarzschild

1 reference

15 August 2017

Graham L Collingridge

5

1 reference

15 August 2017

Borris Ferger

6

1 reference

15 August 2017

Bastian Hengerer

7

1 reference

15 August 2017

Etienne Hirsch

8

1 reference

15 August 2017

Peter Jenner

9

1 reference

15 August 2017

José A Obeso

11

1 reference

15 August 2017

Umberto Spampinato

13

1 reference

15 August 2017

Giora Davidai

14

1 reference

15 August 2017

1 October 2006

1 reference

Nature Reviews Drug Discovery

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

845-854

1 reference

15 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2087

15 August 2017

0 references

cites work

Clinical studies with transdermal rotigotine in early Parkinson's disease

1 reference

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

21 January 2018

1 reference

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

21 January 2018

1 reference

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

21 January 2018

1 reference

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists

21 January 2018

1 reference

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

21 January 2018

1 reference

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

Caffeinated clues from epidemiology of Parkinson's disease

21 January 2018

1 reference

Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease

21 January 2018

1 reference

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

31 March 2020

1 reference

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

31 March 2020

1 reference

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor

31 March 2020

1 reference

Continuous dopamine-receptor stimulation in early Parkinson's disease

31 March 2020

1 reference

Dopamine-receptor stimulation: biobehavioral and biochemical consequences

31 March 2020

1 reference

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

31 March 2020

1 reference

The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

31 March 2020

1 reference

Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.

31 March 2020

1 reference

Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET

31 March 2020

1 reference

Smoking, nicotine and Parkinson's disease

31 March 2020

1 reference

Cholinergic markers in degenerative parkinsonism: autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity.

31 March 2020

1 reference

Anticholinergics for symptomatic management of Parkinson's disease

31 March 2020

1 reference

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

31 March 2020

1 reference

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

31 March 2020

1 reference

Rivastigmine for dementia associated with Parkinson's disease

31 March 2020

1 reference

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

31 March 2020

1 reference

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

31 March 2020

1 reference

Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain

31 March 2020

1 reference

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra

31 March 2020

1 reference

Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture

31 March 2020

1 reference

Smoking and Parkinson's disease: systematic review of prospective studies

31 March 2020

1 reference

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

31 March 2020

1 reference

Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation.

31 March 2020

1 reference

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

31 March 2020

1 reference

5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy

31 March 2020

1 reference

Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway

31 March 2020

1 reference

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

31 March 2020

1 reference

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

31 March 2020

1 reference

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

31 March 2020

1 reference

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models

31 March 2020

1 reference

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

31 March 2020

1 reference

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat

31 March 2020

1 reference

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

31 March 2020

1 reference

Pharmacological actions of the atypical antipsychotic drug clozapine: a review

31 March 2020

1 reference

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

31 March 2020

1 reference

3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

31 March 2020

1 reference

Short-term paroxetine treatment does not alter the motor response to levodopa in PD.

31 March 2020

1 reference

Mirtazapine in L-dopa-induced dyskinesias

31 March 2020

1 reference

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

31 March 2020

1 reference

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

31 March 2020

1 reference

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

31 March 2020

1 reference

Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons

31 March 2020

1 reference

Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid

31 March 2020

1 reference

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

31 March 2020

1 reference

Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment

31 March 2020

1 reference

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

31 March 2020

1 reference

Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist

31 March 2020

1 reference

Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex

31 March 2020

1 reference

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

31 March 2020

1 reference

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

31 March 2020

1 reference

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease

31 March 2020

1 reference

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

31 March 2020

1 reference

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

31 March 2020

1 reference

Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.

31 March 2020

1 reference

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

31 March 2020

1 reference

Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

31 March 2020

1 reference

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.

31 March 2020

1 reference

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

31 March 2020

1 reference

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

31 March 2020

1 reference

Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems

31 March 2020

1 reference

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

31 March 2020

1 reference

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

31 March 2020

1 reference

Opioid peptide processing and receptor selectivity

31 March 2020

1 reference

Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

31 March 2020

1 reference

The molecular basis of opioid receptor function

31 March 2020

1 reference

Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications

31 March 2020

1 reference

Etiology of Parkinson's disease

31 March 2020

1 reference

Molecular Pathways of Neurodegeneration in Parkinson's Disease

31 March 2020

1 reference

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

31 March 2020

1 reference

APOPTOSIS: Death of a Monopoly?

31 March 2020

1 reference

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

31 March 2020

1 reference

Disease modification in Parkinson's disease

31 March 2020

1 reference

Pramipexole protects against MPTP toxicity in non-human primates

31 March 2020

1 reference

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms

31 March 2020

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

31 March 2020

1 reference

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

31 March 2020

1 reference

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

31 March 2020

1 reference

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

31 March 2020

1 reference

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

31 March 2020

1 reference

Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl

31 March 2020

1 reference

Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo

31 March 2020

1 reference

Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.

31 March 2020

1 reference

(-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis

31 March 2020

1 reference

Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl.

31 March 2020

1 reference

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

31 March 2020

1 reference

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

31 March 2020

1 reference

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

31 March 2020

1 reference

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

31 March 2020

1 reference

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease

31 March 2020

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

31 March 2020

1 reference

Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys

31 March 2020

1 reference

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

31 March 2020

1 reference

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

31 March 2020

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

31 March 2020

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

31 March 2020

1 reference

Continuing trials of GDNF in Parkinson's disease

31 March 2020

1 reference

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

31 March 2020

1 reference

Non-motor symptoms of Parkinson's disease: diagnosis and management

31 March 2020

1 reference

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

31 March 2020

1 reference

Buspirone in levodopa-induced dyskinesias

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2087

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference